Entwicklung von Entscheidungshilfen für das organisierte Zervixkarzinom-Screening in Deutschland

Schröer-Günther, Milly; Fechtelpeter, Dennis; Zschorlich, Beate; Wegmann, M.; Keller, Sabine; Schürmann, Christoph; Lampert, Ulrike; Seidl, A.; Janssen, I.; Koch, Klaus

doi:10.1055/a-1028-7283

Cited by 3 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Women between age 20 and 34 now continue to have annual cytology examinations, while women over the age of 34 receive a co-test comprising cytology in combination with a high-risk HPV (hrHPV) test every 3 years. All women aged 20-65 are invited for testing by their health-insurance providers every 5 years (11)(12)(13)(14)(15)(16)(17)(18).…”

mentioning

confidence: 99%

Impact of the Corona Pandemic on Cervical Cancer Screening Assessment

STUEBS,

BEHRENS,

SEIBOLD

et al. 2024

In Vivo

View full text Add to dashboard Cite

Background/Aim: The global impact of the COVID-19 pandemic resulted in disruptions to healthcare systems throughout the world. The numbers of cytology examinations, human papillomavirus (HPV) tests, and women referred for colposcopy decreased in many countries. There have been no reports on cervical cancer screening in Germany. This study aimed to describe changes in the numbers of colposcopies, cytology examinations, HPV tests, and histological results during the pandemic compared to the pre-pandemic years in order to evaluate the impact of the COVID-19 pandemic on cervical cancer screening. Patients and Methods: The numbers of colposcopies, cytology examinations, HPV tests, and histologic results were analyzed retrospectively for the period January 2018 to December 2022. The 2 years period before the pandemic (2018 and 2019) were compared with the 3 years period of the pandemic (2020)(2021)(2022). Results: In total, 6,518 colposcopies were performed in 5,579 women. The numbers of colposcopies, cytology examinations, and high-risk HPV (hrHPV) tests increased during the pandemic years. The number of biopsies per year taken was stable (range=450-554). The relative numbers of cervical intraepithelial neoplasia (CIN) III/HSIL findings were stable, while the numbers of cervical cancers identified increased slightly from 15 (6.6%) in 2018 to 22 (7.4%) in 2022. Conclusion: Increases in numbers of women examined and colposcopies were observed in the years 2021 and 2022 during the pandemic, in comparison to the preceding years. These also led to increases in the figures for cytology, hrHPV, histology, and operations. The onset of the pandemic occurred in the same year as a newly organized screening program started in Germany. The increases might therefore be due to the newly organized screening system.Cervical cancer (CC) is one of the most common cancers amongst women worldwide (1-5). High-grade squamous 734

show abstract

mentioning

confidence: 99%

Impact of the Corona Pandemic on Cervical Cancer Screening Assessment

STUEBS,

BEHRENS,

SEIBOLD

et al. 2024

In Vivo

View full text Add to dashboard Cite

show abstract

Harms and Benefits of Cancer Screening

Robra

2021

Ethical Challenges in Cancer Diagnosis and Therapy

View full text Add to dashboard Cite

Cytology and High-Risk Human Papillomavirus Test for Cervical Cancer Screening Assessment

et al. 2022

View full text Add to dashboard Cite

Background: A new nationwide screening strategy was implemented in Germany in January 2020. No data are available for women referred to certified dysplasia units for secondary clarification after primary diagnosis by a local physician. We therefore investigated combined testing with Papanicolaou smears and high-risk human papillomavirus (hrHPV) and compared the data with the final histological findings. Methods: Between January 2015 and October 2020, all referred women who underwent colposcopy of the uterine cervix in our certified dysplasia unit were included. Cytology findings were classified using the Munich III nomenclature. Results: A total of 3588 colposcopies were performed in 3118 women, along with Pap smear and hrHPV co-testing, followed by histology. Women with Pap II-p (ASC-US) and a positive hrHPV co-test had a 22.4% risk for cervical intraepithelial neoplasia (CIN) 3/high-grade squamous intraepithelial lesion (HSIL). The risk of CIN 3/HSIL was 83.8% in women with Pap IVa-p (HSIL) and a positive hrHPV co-test. A positive hrHPV co-test increased the risk for HSIL+ (OR 5.942; 95% CI, 4.617 to 7.649; p < 0.001) as compared to a negative hrHPV co-test. Conclusions: The accuracy of Pap smears is comparable with the screening results. A positive hrHPV test increases the risk for HSIL+ fivefold. Colposcopy is necessary to diagnose HSIL+ correctly.

show abstract

Entwicklung von Entscheidungshilfen für das organisierte Zervixkarzinom-Screening in Deutschland

Cited by 3 publications

References 20 publications

Impact of the Corona Pandemic on Cervical Cancer Screening Assessment

Impact of the Corona Pandemic on Cervical Cancer Screening Assessment

Harms and Benefits of Cancer Screening

Cytology and High-Risk Human Papillomavirus Test for Cervical Cancer Screening Assessment

Contact Info

Product

Resources

About